Literature DB >> 10446299

Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.

G A Koning1, H W Morselt, M J Velinova, J Donga, A Gorter, T M Allen, S Zalipsky, J A Kamps, G L Scherphof.   

Abstract

A monoclonal antibody against the rat colon carcinoma CC531 was covalently coupled to liposomes containing a dipalmitoylated derivative of the anticancer drug FUdR as a prodrug in their bilayers. We investigated the in vitro interaction of these liposomes with CC531 target cells and the mechanism by which they deliver the active drug FUdR intracellularly to the cells by monitoring the fate of the liposomal bilayer markers cholesterol-[(14)C]oleate and [(3)H]cholesteryloleylether as well as the (3)H-labeled prodrug and colloidal gold as an encapsulated liposome marker. After binding of the immunoliposomes to the cell surface, only limited amounts were internalized as demonstrated by a low level of hydrolysis of liposomal cholesterol ester and by morphological studies employing colloidal gold-labeled immunoliposomes. By contrast, already within 24 h immunoliposome-incorporated FUdR-dP was hydrolyzed virtually completely to the parent drug FUdR intracellularly. This process was inhibited by a variety of endocytosis inhibitors, indicating that the prodrug enters and is processed by the cells by a mechanism involving an endocytic process, resulting in intracellular FUdR concentrations up to 3000-fold higher than those in the medium. Immunoliposomes containing poly(ethyleneglycol) (PEG) chains on their surface, with the antibody coupled either directly to the bilayer or at the distal end of the PEG chains were able to deliver the prodrug into the tumor cells at the same rate as immunoliposomes without PEG. Based on these observations, we tentatively conclude that during the interaction of the immunoliposomes with the tumor cells the lipophilic prodrug FUdR-dP is selectively transferred to the cell surface and subsequently internalized by constitutive endocytic or pinocytic invaginations of the plasma membrane, thus ultimately delivering the prodrug to a lysosomal compartment where hydrolysis and release of parent drug takes place. This concept allows for an efficient delivery of a liposome-associated drug without the need for the liposome as such to be internalized by the cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446299     DOI: 10.1016/s0005-2736(99)00091-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function.

Authors:  Vasundhara Kain; Kevin A Ingle; Romain A Colas; Jesmond Dalli; Sumanth D Prabhu; Charles N Serhan; Medha Joshi; Ganesh V Halade
Journal:  J Mol Cell Cardiol       Date:  2015-04-11       Impact factor: 5.000

2.  Local and average gloss from flat-faced sodium chloride tablets.

Authors:  Mikko Juuti; Bert van Veen; Kai-Erik Peiponen; Jarkko Ketolainen; Valtteri Kalima; Raimo Silvennoinen; Tuula T Pakkanen
Journal:  AAPS PharmSciTech       Date:  2006-01-13       Impact factor: 3.246

3.  Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization.

Authors:  Marjan M Fretz; Anders Høgset; Gerben A Koning; Wim Jiskoot; Gert Storm
Journal:  Pharm Res       Date:  2007-05-31       Impact factor: 4.200

4.  Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery.

Authors:  Kathryn C Partlow; Gregory M Lanza; Samuel A Wickline
Journal:  Biomaterials       Date:  2008-05-16       Impact factor: 12.479

5.  Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases.

Authors:  G A Koning; H W Morselt; A Gorter; T M Allen; S Zalipsky; J A Kamps; G L Scherphof
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

6.  Acute and subchronic (28-day) oral toxicity study in rats fed with novel surfactants.

Authors:  Ranjit Madhukar Bidhe; Sangita Ghosh
Journal:  AAPS PharmSci       Date:  2004-04-07

7.  Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison.

Authors:  Gerben A Koning; Henriëtte W M Morselt; Arko Gorter; Theresa M Allen; Samuel Zalipsky; Gerrit L Scherphof; Jan A A M Kamps
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

8.  MRI of ICAM-1 upregulation after stroke: the importance of choosing the appropriate target-specific particulate contrast agent.

Authors:  Lisette H Deddens; Geralda A F van Tilborg; Annette van der Toorn; Kajo van der Marel; Leonie E M Paulis; Louis van Bloois; Gert Storm; Gustav J Strijkers; Willem J M Mulder; Helga E de Vries; Rick M Dijkhuizen
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

9.  Improving intracellular doxorubicin delivery through nanoliposomes equipped with selective tumor cell membrane permeabilizing short-chain sphingolipids.

Authors:  Lília R Cordeiro Pedrosa; Albert van Hell; Regine Süss; Wim J van Blitterswijk; Ann L B Seynhaeve; Wiggert A van Cappellen; Alexander M M Eggermont; Timo L M ten Hagen; Marcel Verheij; Gerben A Koning
Journal:  Pharm Res       Date:  2013-05-11       Impact factor: 4.200

10.  CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis.

Authors:  Elmieke P J Boot; Gerben A Koning; Gert Storm; Josée P A Wagenaar-Hilbers; Willem van Eden; Linda A Everse; Marca H M Wauben
Journal:  Arthritis Res Ther       Date:  2005-03-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.